Our top heart failure articles of the year cover a modern development for dapagliflozin, address the important issue of indigestion in this area, and see coronavirus disease 2019 make yet another appearance.
The heart failure field has seen several positive developments this year – most recently, Entresto (sacubitril / valsartan) to treat heart failure with a conserved ejection fraction. Our main article of the year covers another: Dapagliflozin, originally developed to treat diabetes, was approved by the FDA to treat smaller ejection fraction disease.
Three of our remaining top 5 addresses the important issue of inequalities, while coronavirus 2019 (COVID-19) is making yet another appearance, in a year that has been pandemics see most, if not all, of the medical world.
5. Heart failure publications, experimental research continues with lack of female authors
Twenty percent of first authors and less than 15% of top authors are in studies aimed at researching women’s heart failure, this study reveals from September. The bite? Women make up a quarter of doctors and researchers instead of heart failure. These figures include the United States and Europe, and both saw industry-sponsored trials as likely to be female authors compared to government-sponsored and nonprofit trials / university.
Read the full article.
4. How do hospitals for heart failure differ before vs. during the COVID-19 period?
This Australian study showed that patients hospitalized for heart failure during the pandemic had a more advanced disease and were more sympathetic, despite hospitals for the disease falling by 41% between March and April. They also had higher average blood pressure (144/77 vs 136/74 mm Hg), more cases of New York Heart Association class III / IV infection (97% vs 68%), and fewer prescriptions for patients. -enzyme-protected enzyme-borne angiotensin / angiotensin receptor blockers (35% vs. 57%) compared with patients admitted before pandemic.
Read the full article.
3. QOL negatively affects non-cardiovascular associations in patients with chronic heart failure
Several comorbid conditions have been shown to adversely affect health-related quality of life (HRQOL). For example, HRQOL depression caused 200% worse; anemia / iron deficiency, 25.6% worse; diabetes, 21.8% worse; and respiratory disease, 21.3% worse compared to patients with heart failure who did not have these comorbidities. The authors of the study called for the integration of clinical governance of comorbidity, as this not only improves QOL development but also social benefits.
Read the full article.
2. Racial differences persist for patients with congestive heart failure
In a year where race-related issues were on the rise and in the middle, this analysis of 15-year-old data showed that non-Hispanic blacks were the most likely heart failure vs. semi-Hispanic White and Mexican Americans: 5017 Vs. 2746 and 2508, respectively, for 2013 through 2016. Higher levels, and earlier onset, of several risk factors among black men and women, and these include obesity, may be diabetes and hip tolerance. Socio-economic factors can contribute, so public policies should focus specifically on this patient population to close the gender discrimination gap and reap the benefits of early diagnosis .
Read the full article.
1. FDA Approves Dapagliflozin to Treat Heart Failure, Breaking New Ground in SGLT2 Competition
This agreement marked the first time a sodium-glucose cotransporter 2 (SGLT2) inhibitor received a signal for use in adults with heart failure with a smaller ejection fraction (HFrEF). Making this improvement even more interesting is that adults with HFrEF do not have comorbid type 2 diabetes (T2D) to use it. SGLT2 protectors include a type of drug that was originally developed to treat diabetes. Dapagliflozin was previously approved by the FDA in 2019 for use in adults with comorbid T2D and cardiovascular disease or other risk factors, to reduce the risk of hospitalization.
Read the full article.